Corbus Pharmaceuticals Holdings Inc
(NASDAQ : CRBP)

( )
CRBP PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.53%87.991.3%$894.47m
AMGNAmgen Inc.
0.04%191.311.2%$560.48m
ONCESpark Therapeutics, Inc.
0.33%113.9611.2%$458.43m
GILDGilead Sciences, Inc.
-0.93%65.020.9%$450.52m
BIIBBiogen Inc.
-1.28%325.651.3%$354.96m
BPTHBio-Path Holdings, Inc.
-5.48%27.79190.1%$296.94m
REGNRegeneron Pharmaceuticals, Inc.
-1.66%407.602.6%$280.72m
ILMNIllumina, Inc.
-1.31%305.783.5%$269.47m
VRTXVertex Pharmaceuticals Incorporated
-0.32%187.481.9%$245.27m
SRPTSarepta Therapeutics, Inc.
-1.20%126.8215.4%$210.77m
EXASExact Sciences Corporation
-3.44%91.9325.3%$194.56m
ALXNAlexion Pharmaceuticals, Inc.
-1.90%133.512.0%$181.24m
AAgilent Technologies, Inc.
-0.16%80.971.6%$153.74m
IONSIonis Pharmaceuticals, Inc.
1.25%79.528.3%$101.55m
BMRNBioMarin Pharmaceutical Inc.
-1.24%93.364.3%$97.41m

Company Profile

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded on December 18, 2013 and is headquartered in Norwood, MA.